Published in Radiat Oncol on February 04, 2011
Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood (2012) 1.26
Treatment planning study of the 3D dosimetric differences between Co-60 and Ir-192 sources in high dose rate (HDR) brachytherapy for cervix cancer. J Contemp Brachytherapy (2012) 1.08
The future of Radiation Oncology: Considerations of Young Medical Doctor. Rep Pract Oncol Radiother (2012) 0.79
Study of the dosimetric differences between (192)Ir and (60)Co sources of high dose rate brachytherapy for breast interstitial implant. Rep Pract Oncol Radiother (2016) 0.78
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol (2005) 4.68
Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys (1995) 3.05
Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol (2007) 2.32
Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA (2010) 2.16
Current status and future potential of advanced technologies in radiation oncology. Part 2. State of the science by anatomic site. Oncology (Williston Park) (2009) 2.08
Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? J Health Econ (1999) 2.06
Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol (2008) 2.00
Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys (2010) 1.97
An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol (2008) 1.89
Intensity-modulated radiation therapy use in the U.S., 2004. Cancer (2005) 1.78
Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol (2000) 1.77
Technical note: Dosimetric study of a new Co-60 source used in brachytherapy. Med Phys (2007) 1.59
Different styles of image-guided radiotherapy. Semin Radiat Oncol (2007) 1.57
Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys (2001) 1.43
Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.33
Monte Carlo dosimetric study of the BEBIG Co-60 HDR source. Phys Med Biol (2005) 1.29
Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys (1998) 1.26
Radiation therapy with charged particles. Semin Radiat Oncol (2006) 1.18
Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys (2000) 1.16
Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes (2003) 1.13
Hypofractionation for prostate cancer radiotherapy--what are the issues? Int J Radiat Oncol Biol Phys (2003) 1.12
Has the time come for doing away with Cobalt-60 teletherapy for cancer treatments. J Med Phys (2009) 1.12
Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol (2008) 1.11
A survey of image-guided radiation therapy use in the United States. Cancer (2010) 1.10
Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol (2008) 1.04
High Dose Rate Brachytherapy in the Treatment of cervical cancer: preliminary experience with cobalt 60 Radionuclide source-A Prospective Study. Clin Med Insights Oncol (2010) 1.04
Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol (1998) 0.98
PET/CT staging followed by Intensity-Modulated Radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison. Radiat Oncol (2007) 0.97
Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol (2004) 0.94
Current status and future potential of advanced technologies in radiation oncology. Part 1. Challenges and resources. Oncology (Williston Park) (2009) 0.93
A comparison between cobalt and linear accelerator-based treatment plans for conformal and intensity-modulated radiotherapy. Br J Radiol (2008) 0.92
American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.92
On the use of HDR 60Co source with the MammoSite radiation therapy system. Med Phys (2008) 0.92
International perspectives on quality assurance and new techniques in radiation medicine: outcomes of an IAEA conference. Int J Radiat Oncol Biol Phys (2008) 0.91
Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate (2004) 0.87
The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: observations on efficacy and toxicity in clinical practice. Semin Radiat Oncol (2008) 0.82
A comprehensive review of prostate cancer brachytherapy: defining an optimal technique. Int J Radiat Oncol Biol Phys (1999) 0.81
Planning cancer control in Latin America and the Caribbean. Lancet Oncol (2013) 8.43
Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys (2004) 7.32
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01
Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources--1950-2007. Radiology (2009) 5.48
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma: report from Image-Guided Brachytherapy Working Group. Int J Radiat Oncol Biol Phys (2004) 2.98
Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys (2011) 2.86
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Bioeffect modeling and equieffective dose concepts in radiation oncology--terminology, quantities and units. Radiother Oncol (2012) 2.49
The Radiological Physics Center's standard dataset for small field size output factors. J Appl Clin Med Phys (2012) 2.14
Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2005) 1.90
Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys (2010) 1.76
Status of radiotherapy resources in Africa: an International Atomic Energy Agency analysis. Lancet Oncol (2013) 1.74
Design, development, and implementation of the radiological physics center's pelvis and thorax anthropomorphic quality assurance phantoms. Med Phys (2007) 1.56
Effects of amifostine on radiation-induced cardiac damage. Acta Oncol (2003) 1.45
Transition in survival from low-dose hyper-radiosensitivity to increased radioresistance is independent of activation of ATM Ser1981 activity. Int J Radiat Oncol Biol Phys (2007) 1.41
Towards better and safer use of radiation in medicine. Lancet (2010) 1.39
A dosimetric uncertainty analysis for photon-emitting brachytherapy sources: report of AAPM Task Group No. 138 and GEC-ESTRO. Med Phys (2011) 1.34
Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: report of the AAPM and ESTRO. Med Phys (2012) 1.31
Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther (2004) 1.30
Third-party brachytherapy source calibrations and physicist responsibilities: report of the AAPM Low Energy Brachytherapy Source Calibration Working Group. Med Phys (2008) 1.29
Supplement to the 2004 update of the AAPM Task Group No. 43 Report. Med Phys (2007) 1.28
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
Credentialing of institutions for IMRT in clinical trials. Int J Radiat Oncol Biol Phys (2004) 1.26
Accuracy of two heterogeneity dose calculation algorithms for IMRT in treatment plans designed using an anthropomorphic thorax phantom. Med Phys (2007) 1.26
A method for evaluating quality assurance needs in radiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.22
Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 1.19
Intensity-modulated radiation therapy for gynecologic cancers: pitfalls, hazards, and cautions to be considered. Semin Radiat Oncol (2006) 1.17
Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 1.09
The effects of G2-phase enrichment and checkpoint abrogation on low-dose hyper-radiosensitivity. Int J Radiat Oncol Biol Phys (2010) 1.09
American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int J Radiat Oncol Biol Phys (2009) 1.08
Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation. BMC Genomics (2005) 1.07
Influence of mast cells on structural and functional manifestations of radiation-induced heart disease. Cancer Res (2005) 1.06
Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer (2008) 1.06
Technical note: Heterogeneity dose calculation accuracy in IMRT: study of five commercial treatment planning systems using an anthropomorphic thorax phantom. Med Phys (2008) 1.03
Safety considerations for IMRT: executive summary. Med Phys (2011) 1.02
Reference photon dosimetry data and reference phase space data for the 6 MV photon beam from varian clinac 2100 series linear accelerators. Med Phys (2005) 1.01
Effects of exposure to low-dose-rate (60)co gamma rays on human tumor cells in vitro. Radiat Res (2002) 0.98
Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res (2006) 0.98
Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy. Med Dosim (2010) 0.97
Neutron source strength measurements for Varian, Siemens, Elekta, and General Electric linear accelerators. J Appl Clin Med Phys (2003) 0.96
Angular dependence of the nanoDot OSL dosimeter. Med Phys (2011) 0.96
Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Strahlenther Onkol (2004) 0.96
Toxicity from radiation in breast cancer. Cancer Treat Res (2006) 0.94
MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med (2007) 0.94
American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.92
Rectal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 0.92
Invasive breast cancer. J Natl Compr Canc Netw (2007) 0.92
How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol (2003) 0.91
X-ray imaging and the skin: radiation biology, patient dosimetry and observed effects. Radiat Prot Dosimetry (2005) 0.91
Soft tissue sarcoma. J Natl Compr Canc Netw (2007) 0.91
AAPM Task Group 103 report on peer review in clinical radiation oncology physics. J Appl Clin Med Phys (2005) 0.91
Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury. Radiother Oncol (2011) 0.91
Estimating the lowest detectable dose of ionizing radiation by the cytokinesis-block micronucleus assay. Radiat Res (2013) 0.90
American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys (2010) 0.89
Dosimetric prerequisites for routine clinical use of photon emitting brachytherapy sources with average energy higher than 50 kev. Med Phys (2007) 0.88
Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer. J Thorac Oncol (2011) 0.88
Colon cancer. J Natl Compr Canc Netw (2007) 0.87
American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for Intensity-modulated Radiation Therapy (IMRT). Am J Clin Oncol (2012) 0.86
Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003. Radiat Res (2003) 0.86
Anthropomorphic breast phantoms for quality assurance and dose verification. J Appl Clin Med Phys (2004) 0.84
Intraluminal brachytherapy in the management of squamous carcinoma of the esophagus. Dis Esophagus (2009) 0.83
Dosimetry in an IMRT phantom designed for a remote monitoring program. Med Phys (2008) 0.83
Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol (2005) 0.82
Gene expression-based detection of radiation exposure in mice after treatment with granulocyte colony-stimulating factor and lipopolysaccharide. Radiat Res (2011) 0.82
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol (2015) 0.82
Comparison of electron beam characteristics from multiple accelerators. Int J Radiat Oncol Biol Phys (2004) 0.82
Radioprotection of lung tissue by soy isoflavones. J Thorac Oncol (2013) 0.82
Differential effect of soy isoflavones in enhancing high intensity radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinoma. Radiother Oncol (2013) 0.82
Relative stopping power measurements to aid in the design of anthropomorphic phantoms for proton radiotherapy. J Appl Clin Med Phys (2014) 0.81
Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl Oncol (2011) 0.81
Rectal cancer. J Natl Compr Canc Netw (2007) 0.81
Development of a modified head and neck quality assurance phantom for use in stereotactic radiosurgery trials. J Appl Clin Med Phys (2013) 0.81
Local control in advanced cancer of the nasopharynx: is a boost dose by endocavitary brachytherapy of prognostic significance? Brachytherapy (2012) 0.80
The evaluation of low dose hyper-radiosensitivity in normal human skin. Radiother Oncol (2004) 0.80
Radiation-induced adaptive response is not seen in cell lines showing a bystander effect but is seen in lines showing HRS/IRR response. Int J Radiat Biol (2009) 0.80
Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin. Cancer Gene Ther (2005) 0.80
B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer. Cancer Lett (2011) 0.80
Relationships among micronuclei, nucleoplasmic bridges and nuclear buds within individual cells in the cytokinesis-block micronucleus assay. Mutagenesis (2013) 0.79
Residual late radiation damage in mouse stromal tissue assessed by the tumor bed effect. J Radiat Res (2007) 0.79
"SABER": A new software tool for radiotherapy treatment plan evaluation. Med Phys (2010) 0.79
Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer. Am J Clin Oncol (2014) 0.79
Change in creatinine clearance over time following upper abdominal irradiation: a dose-volume histogram multivariate analysis. Am J Clin Oncol (2011) 0.78
The American Board of Radiology Holman Research Pathway: 10-year retrospective review of the program and participant performance. Int J Radiat Oncol Biol Phys (2012) 0.78
A reanalysis of the Collaborative Ocular Melanoma Study Medium Tumor Trial eye plaque dosimetry. Int J Radiat Oncol Biol Phys (2003) 0.78
Thermoluminescence dosimetry measurements of brachytherapy sources in liquid water. Med Phys (2008) 0.78
Soy Isoflavones Promote Radioprotection of Normal Lung Tissue by Inhibition of Radiation-Induced Activation of Macrophages and Neutrophils. J Thorac Oncol (2015) 0.77
A novel method of boron delivery using sodium iodide symporter for boron neutron capture therapy. J Radiat Res (2010) 0.77
The International Atomic Energy Agency (IAEA): an active role in the global fight against cancer. Radiother Oncol (2011) 0.77
Anal canal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 0.77
Characteristic 8 keV X rays possess radiobiological properties of higher-LET radiation. Radiat Res (2010) 0.77
Radiotherapy for breast cancer in countries with limited resources: program implementation and evidence-based recommendations. Breast J (2006) 0.77
Safety in radiation oncology: the role of international initiatives by the International Atomic Energy Agency. J Am Coll Radiol (2011) 0.76